Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT07041528

Perceptions of De-implementing Routine Follow-ups After Hip and Knee Arthroplasty

How Do Patients and Health Care Professionals Perceive De-implementation of Routine Follow-ups After Total Hip and Knee Arthroplasty? Protocol for a Nested Qualitative Study Within a Hybrid De-implementation Trial

Status
Not Yet Recruiting
Phase
Study type
Observational
Enrollment
90 (estimated)
Sponsor
Tergooi Medical Center · Academic / Other
Sex
All
Age
50 Years
Healthy volunteers
Not accepted

Summary

After undergoing total hip or total knee arthroplasty, current guidelines recommend routine follow-up with an X-ray within 3 months and again at 1 year. Follow-up at 5 years (for hip arthroplasties) or every 5 years (for knee arthroplasties) is also considered worthwhile according to the guidelines. However, these follow-up appointments require considerable time from patients, caregivers, and healthcare professionals, and it is unclear whether they are truly beneficial. It is possible that a single follow-up within 3 months is sufficient. This could potentially prevent over 100,000 unnecessary hospital visits per year, resulting in significant cost savings. If patients or healthcare providers have concerns, they can always request an additional follow-up. The HAKA trial consists of three different work packages (WPs).The quantitative work packages 1 (WP1) and 2 (WP2) will investigate the 1-year and 10-year follow-up. The qualitative third work package (WP3) will explore and compare the patients' and health care professionals' (HCPs) experiences with, and perceptions about, RFU and COD after total hip and knee arthroplasty. The aim of the overarching HAKA-trial is to safely reduce routine follow-up appointments after total hip or knee arthroplasty and to revise current clinical guidelines accordingly.

Conditions

Timeline

Start date
2026-09-01
Primary completion
2028-06-01
Completion
2028-06-01
First posted
2025-06-27
Last updated
2025-06-27

Locations

1 site across 1 country: Netherlands

Source: ClinicalTrials.gov record NCT07041528. Inclusion in this directory is not an endorsement.